In the BioHarmony Drug Report Database

"Preview" Icon

Midazolam maleate

Midazolam, Nayzilam, Buccolam (midazolam maleate) is a small molecule pharmaceutical. Midazolam maleate was first approved as Midazolam on 2011-09-04. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy. It is known to target Alpha-1B adrenergic receptor. Buccolam’s patents are valid until 2038-06-20 (FDA).

 

Trade Name

 

Buccolam
 

Common Name

 

midazolam maleate
 

ChEMBL ID

 

CHEMBL2106922
 

Indication

 

anxiety disorders, epilepsy, psychomotor agitation, status epilepticus
 

Drug Class

 

Benzodiazepine

Image (chem structure or protein)

Midazolam maleate structure rendering